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The recent exciting advances in ourunderstanding of the regulation of the energy sensor 
AMP-activated protein kinase (AMPK), together with renewed appreciation of its 
importance in maintaining cellular function, brought together leading scientists at a 
recent FASEB-sponsored meeting inSeptember 2014. Here, we report some of the 
highlights of this conference. 
 
 
Introduction 
 
The AMP-activated protein kinase (AMPK) is a sensor of cellular energy status that 
directs metabolic adaptation to support cellular growth and survival. AMPK is activated 
by changes in the cellular AMP:ATP and ADP:ATP ratios, and functions to restore energy 
homeostasis by switching off biosynthetic pathways consuming ATP while switching on 
catabolic pathways that produce ATP. Over the last 20years, the AMPK field has grown 
enormously from a few dozen papers to over 1000 published per year. The field has 
grown from a group of ten to twelve investigators interested in the biological actions of 
AMPK in the 1990s to literally hundreds of investigators worldwide studying this 
pathway. Indeed, recent research has expanded the paradigm of AMPK as a metabolic 
sensor and to the more global concept that AMPK has broad effects on cellular function, 
providing synergy between research in energy metabolism and other areas of science 
such as cancer and immunology. The downstream actions of AMPK regulate numerous 
steps in cellular metabolism, cell growth, organelle regulation including mitochondrial 
biogenesis, autophagy, oxidative stress and cell polarity.As a result, AMPK is an 
attractive target for the development of drugs aimed at preventing and/or treating 
metabolic diseases and cancer.Recent breakthroughs in the field of AMPK research were 
presented on the occasion of a FASEB Scientific Research Conference entitled “AMPK: 
biological action and therapeutic perspectives”. This was the 8th international 
conference in the series (the original conference was held in Boston in 2000, organized 
by Dr. Neil Ruderman, Boston Medical Center/Boston University School of Medicine) 
with the last fivemeetingsorganized on the behalf of FASEBScientific Research 
Conference. Thislast conference was held from September 28 to October 3, 2014, in the 
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picturesque town of Barga, just outside of Lucca, in Italy. In a beautiful location 
providing an inspiring and intimate setting,scientists from 22 different countries 
gathered together to discuss basic AMPK biology and provide future direction for AMPK 
therapy in disease-focused research (Figure 1).More than 50 excellent and varied talks, 
including studies of basic and clinical relevance, addressed recent breakthroughs in the 
expanding field of AMPK. It would not be possible to provide a comprehensive report of 
all of the talks, and so in this short report, wehaveselected some of the highlights that 
arose during the meeting.  
 
 
Deconstructing the complexity of AMPK regulation. 
AMPK is a heterotrimeric complex composed of one catalytic -subunit comprising a 
typical Ser/Thr kinase domain, one scaffold -subunit containing a carbohydrate 
binding module (CBM) and one regulatory -subunit containingfour cystathionine--
synthase (CBS) domains, that serve tobind adenine nucleotides. The mechanism of 
AMPK activation involves two steps, a reversible phosphorylation at a conserved 
residue (Thr172 in the rat catalytic subunit sequence) within the activation loop in the 
-subunit, and a stimulatory allosteric effect upon binding of AMP within the CBS 
domains of the -subunit. In addition, AMP and ADP binding regulates AMPK by 
promoting Thr172 phosphorylation by the upstream kinases, liver kinase B1 (LKB1) and 
Ca2+/calmodulin dependent protein kinase kinase  (CaMKK), and by protecting 
Thr172 from dephosphorylation by phosphatases. All these effects of AMP are 
antagonized by binding of ATP, providing a very sensitive mechanism for the activation 
of AMPK in conditions of cellular energy stress. Grahame Hardie (University of Dundee) 
reviewed the current knowledge of the “canonical” mechanisms for the regulation of 
AMPK by energy stress and presented alternative “non-canonical” mechanisms, 
including activation by CaMKK, and repression by Akt and other kinases. Recent 
studies suggested that phosphorylation of a serine/threonine-rich insert (ST loop) 
within the -subunit inhibits subsequent phosphorylation of Thr172 by blocking access 
of upstream kinases LKB1 or CaMKK to Thr172 and represents antagonistic 
mechanisms to downregulate AMPK signaling (Hawley et al., 2014). Yvonne Oligschläger 
(Maastricht University) provided new insight into the regulation of glycogen binding to 
AMPK through autophosphorylation at Thr148 within the CBM of the -subunit. Thr148 
phosphorylation was found to inhibit glycogen localization of AMPK thus affecting 
cellular glycogen turnover(Oligschlaeger et al., 2015).Shengcai Lin (Xiamen University) 
presented a novelmechanism by which AMP regulatesAMPK activation. In response to 
starvation or exogenous AMP, AMP binding triggers the interaction between 
myristoylated AMPK and the scaffold protein AXIN that also binds to LKB1. Of note, ADP 
has no effect on the AXIN-based complex formation. The formation of the AXIN-AMPK-
LKB1 complex facilitates the phosphorylation of AMPK by LKB1 and causes AMPK 
activation.In follow-up studies, it was demonstrated that this mechanism occurs at the 
late endosome/ lysosome surface and is dependent on the v-ATPase-Ragulator complex 
(Zhang et al., 2014). Interestingly, v-ATPase and Ragulator proteinsare known to be 
important componentsfor recruiting and activating mechanistic target of rapamycin 
complex-1 (mTORC1) to the lysosome under nutrient-rich conditions. These results 
suggest a general role of late endosome/lysosome in sensing of nutrient by both the 
AMPK and the mTORC1 signaling pathways, thereby providing a switch between 
catabolism and anabolism.The functional consequence for AMPK recruitment at the late 
endosomal/lysosomal protein complex v-ATPase/ Ragulator on the inverse relationship 
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between AMPK and mTORC1 signaling pathways were discussed. To add a further layer 
of complexity in the regulation of AMPK activation, Bruce Kemp (St Vincent Institute of 
Medical Research and University of Melbourne) provided evidence for activation of 
naive AMPK independently of Thr172 phosphorylation(Scott et al., 2014). The small 
molecule AMPK activator A769662 was found to activate AMPK not phosphorylated on 
Thr172.In contrast to adenine nucleotides, A-769662 does not bind the -subunit but 
requires the -subunit and its autophosphorylation at Ser108 within the CBM to 
allosterically activate AMPK.Interestingly, a synergistic AMPK activation was found with 
the combination of A-769662 and AMP, independently of both-subunit Thr172 and -
subunit Ser108 phosphorylation(Scott et al., 2014). These findings raise the exciting 
possibility that combinatorial strategies based on AMP and small molecule activators 
may be relevant for AMPK-based therapy in disease-focused research and further 
studies are eagerly anticipated. 
 
Over the last few years, knowledge gained through the availability of mammalian AMPK 
crystal structures has fundamentally advanced theunderstandingonthe mechanism by 
which adenine nucleotides regulate AMPK activity. Structural information on AMPK 
complexesmay also help for the design of specific small-molecule activators for clinical 
applications. Crystal structures of AMPK bound with AMP revealed that only three of the 
four potential nucleotide-binding sites within the -subunitcontribute to nucleotide 
regulation.Binding studies using AMPK in solution revealed that two sites (sites 1 and 
3)are competitively bound by either AMP, ADP, orATP. In contrast, nucleotide bound as 
site 4 was not exchangeable. Site 2 is unoccupied,possibly because this site lacks an 
aspartate residue found in the other sites that interacts with the ribose ring of the bound 
nucleotide. Binding of AMP at site 1 was assigned to the effect on allosteric activation, 
whereas binding of AMP or ADP at site 3 to the protection against dephosphorylation.An 
important breakthrough came from the crystal structure of AMPK regulatory core 
fragment and the kinase domain of the -subunitproviding insights on the 
conformational changes induced by binding of adenine nucleotides and the dynamics of 
communication among the different subunits.Flexible components from the -subunit 
(-RIM/-hook) interact with the exchangeable nucleotide-binding site 3 on the -
subunitand favor a conformation change in which Thr172 interacts with the C-terminal 
regions of the α- and β-subunits, offering a protection against dephosphorylation.Steve 
Gamblin (The Francis Crick Institute) presented results based on structural studies 
forfull-length human AMPK α2β1γ1 heterotrimer in complex with the small molecule 
activators991 and A-769662(Xiao et al., 2013). The molecular mechanismsfor these two 
compounds arevery similar asthey bind to the same site localized at the interface of the 
kinase domain and the CBM of the -subunit.Binding of 991 and A-769662 stabilizes the 
interaction between the CBM and the kinase domain, which in turn has a stabilizing 
effect on the interaction of the activation loop structure, enhancingthe protection 
against dephosphorylation of T172.In addition to X-ray crystallography data, Matt 
Sanders (The Francis Crick Institute) presented results from biophysical methods 
(circular dichroism andbiolayer interference) to compare binding of small molecule 
activators to AMPK complexes, showing that compound 991 binds significantly tighter 
to α2/α1β1γ1and α1β2γ1heterotrimers than A-769662. Ravi Kurumbail (Pfizer) 
described similar molecular mechanisms based on the crystal structure of full-length 
α2β1γ1 heterotrimer bound with a series of ligands related to A-769662 (Calabrese et 
al., 2014). A-769662 and its analog bind to a novel allosteric pocket between the CBM 
and the kinase domain, and mediate their effects primarily through decreasing Km for 
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the substrate peptide. In contrast, adifferent molecular mechanism has been reported 
for AMP, which regulates AMPK by increasing the Vmax of phosphorylation reaction. Uwe 
Schlattner (INSERM and UniversityGrenoble Alpes) presented a complementary 
approach to structural studies to gain insight into the role of CBS domains for allosteric 
AMPK activation. Hedeveloped an AMPK FRET sensorbased on the nucleotide-induced 
conformational switch model. This molecular sensorallows a direct and real-time 
readout of the AMPK conformational change upon ligand bindingand may be exploited 
for various analytical applications as well as versatile tools for screening and in vivo 
applications. 
 
 
Peripheral and central regulation of energy balance by AMPK 
Although AMPK was originally identified as asensor of cellular energy status by 
coordinating anabolic and catabolic pathways to balance nutrient supply with energy 
demand, it is now clear that it also participates in the controlof whole-body energy 
homeostasis by integrating signals from the cellular environment and whole organism. 
There are a number of hormones involved in the regulation of whole-body energy 
balance which alter AMPK activation. Takashi Kadowaki (University of Tokyo) discussed 
the role of AMPK in mediating the anti-diabetic and anti-atherogenic actions of 
adiponectin,a hormone that is derived from adipose tissue and is reduced in obesity-
linked diseases. Adiponectin exerts its effects by binding to the adiponectin receptors, 
AdipoR1 and AdipoR2,which mediate increased AMPK and peroxisome proliferator-
activated receptor (PPAR)- activities to regulate normal glucose and lipid metabolism 
and insulin sensitivity.He reported the identification of an orally active small-molecule 
AdipoR1/R2 agonist termed AdipoRon with very similar effects to adiponectin in muscle 
and liver, with activation of AMPK and PPAR- pathwaysand ameliorated insulin 
resistance and glucose intolerance in obese diabetic mice on a high-fat diet (Okada-
Iwabu et al., 2013).Another layer of signal integration for the regulation of whole-body 
energy balance happens at the level of hypothalamic AMPK that acts by controlling both 
feeding and energy expenditure. Miguel López (Universidade deSantiago de 
Compostella) further emphasized the role of AMPK inthe ventromedial nucleus of the 
hypothalamus as a central integrator of peripheral signals and mediator of the effects of 
thyroid hormones, bone morphogenetic protein 8B (BMP8B), nicotine and oestradiol on 
the regulation of peripheral metabolism and particularly,brown adipose tissue 
thermogenesis(Martinez de Morentin et al., 2014). 
 
 
Investigating emerging AMPK signaling pathways 
AMPK regulates a wide array of physiological events and, consistently, is expected to 
have a tremendous impact on survival, growth and development at the organismal level. 
In addition, impairment of the metabolic control of AMPK has been associated with the 
pathological context as well as in many prevalent human diseases including type 2 
diabetes, insulin resistance,cardiovascular diseases and cancer. In order to explore more 
deeply the various signaling pathway controlled by AMPK, many groups have generated 
and analyzed various animal models, ranging from rodents to the worm C. elegans. 
Pascal Froment (INRA) talked about the role of AMPK in male and female reproduction. 
Male mice deficient in AMPK1 show a decrease in fertility due to 
structuralabnormalities and alterations in the motility of spermatozoa. Results from 
mice deficient in AMPK1 in the Sertoli cells established the importance of AMPK on 
 5 
Sertoli-germ cell interactions and shaping of the sperm head. Deletion of AMPK1 in the 
oocyte also revealed a role for AMPK on oocyte quality and oocyte/somatic cell 
communication(Bertoldo et al., 2015). Richard Roy (McGill University) used C. elegansto 
demonstrate how AMPK coordinates the initiation of germ line stem cell division with 
environmental conditions. During periods of nutrient/energy stress, AMPK is requiredto 
buffer adverse epigenetic processes in these cells that ultimately cause reproductive 
defects in subsequent unstressed generations. 
 
Ian Salt (University of Glasgow) focused on the role of AMPK in adipose tissue, 
influencing not only metabolism in adipocytesbut also acting to suppress pro-
inflammatory signaling pathways. He also discussed the importance of perivascular 
adipose tissue (PVAT) in the pathophysiology of cardiovascular disease and how 
dysregulation of AMPK in PVAT can influence vascular function in obesity. In the same 
vein, Neil Ruderman (Boston University Medical Center)described diminished AMPK 
activity in multiple adipose tissue depots from insulin resistant patients. This is 
associated with oxidative stress, increased expression of inflammatory cytokines and 
decreased expression oxidative phosphorylation genes in visceral fat.By contrast, the 
marked increase in insulin sensitivity observed post bariatric surgery is accompanied by 
a significant increase in AMPK activity and decreased oxidative stress in subcutaneous 
fat. 
 
AMPK has emerged as a key mediator of the adaptation to environmental cues. Mark 
Evans (University of Edinburgh) provided genetic evidence for the contribution of AMPK 
to ventilatory adjustments during hypoxia in that mice lacking AMPK exhibit 
hypoventilation and apneas rather than hyperventilation. Thus AMPK signaling links 
oxygen to energy supply at the whole-body level. Rémi Mounier (CNRS and Université 
Claude Bernard Lyon1) spoke about the regulation of stem cell fate during post-natal 
skeletal muscle regeneration. In response to muscle injury, muscle stem cells(also called 
satellite cells)become activated and trigger cellular reprogramming that results in 
enhanced proliferation, differentiation, and/or self-renewal. By using mice deleted of 
AMPK1 in satellite cells, he showed that AMPK orchestrates muscle stem cell fate by 
promoting metabolic reprogramming. 
 
 
AMPK incancer: friend or foe? 
More than 10 years ago, the discovery of the tumor suppressor LKB1 as an upstream 
kinase of AMPK established a direct connection between the regulation of energy 
metabolism and cancer. However, accumulated data indicate that the functional role of 
AMPK in cancer initiation and progression is much more complex than expected. On one 
hand, AMPK can mediate the tumor suppressive signaling of LKB1 and is anti- 
tumorigenic; on the other hand AMPK is required for cancer cell survival under 
metabolic stress such as hypoxia and glucose deprivation and is pro-tumorigenic. Thus, 
depending on the context, AMPK has a dual role in carcinogenesis. Almut Schulze 
(Universitat Würzburg) reminded the participants that cancer cells undergo unique 
metabolic reprogramming during transformation and many oncogenic signaling 
pathways directly regulate the activity of metabolic processes to support unrestrained 
cell growth(Lewis et al., 2015). Rosa Señaris (Universidade de Santiago de Compostella) 
discussed the involvement of AMPK in the initiation and progression of astrocytic 
tumors.She demonstrated that AMPK is found constitutively activated in astrocytes 
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expressing oncogenic HRasV12 and help to coordinately support high cell division rates 
by increasing extracellular lipid internalisation and reducing energy expenditure 
through the inhibition of de novofatty acid synthesis(Rios et al., 2014).Conversely, 
Tracey Rouault (NIH) provided an example where AMPK acts as a tumor suppressor in 
hereditary renal cancer caused by fumarate hydratase (FH) deficiency. Reduced AMPK 
activity contributes to the oncogenic growth of FH-deficient cells by promoting lipid 
synthesis and anabolic reactions (Tong et al., 2011).Along the same line, Russell Jones 
(McGill university) demonstrated that AMPK can function as a tumor suppressor in Myc-
dependent lymphoma. Disruption of AMPK signaling promotes metabolic 
reprogramming of cancer cells withstabilization of the hypoxia-inducible factor-1 (HIF-
1) to drive the Warburg effect.In this context, he presented evidence supporting a role 
for AMPK in the control of mitochondrial OXPHOS and ROS production. Dave Carling 
(MRC Clinical Sciences Centre) discussed the role of AMPK cascade in prostate cancer 
progression, and presented evidence that activation of AMPK in prostate cancer cells 
increases cell migration. 
 
Annapoorni Rangarajan (Indian Institute of Science) presented a novel role for AMPK in 
the acquisition of anoikis-resistance, a hallmark of solid tumors. By phosphorylating the 
anti-apoptotic protein PEA15, AMPK contribute to the anchorage-independent growth 
of breast cancer cells(Hindupur et al., 2014). She evoked the exciting possibility that 
targeting the AMPK-PEA15 axis might prevent breast cancer dissemination and 
metastasis. Masahisa Jinushi (Hokkaido University) is interested in molecular 
mechanisms by which macrophage-mediated phagocytosis of tumor cells and regulates 
tumor immunosurveillance. He described the participation of AMPK1 with T cell 
immunoglobulin- and mucin domain-containing molecule-4 (TIM-4) in the activation of 
autophagic processes,which are critical for degrading ingested tumors and their 
associated antigens(Baghdadi et al., 2013). These results indicate that targeting the TIM-
4-AMPK1 interaction may constitute a unique strategy for augmenting antitumor 
immunity and improving cancer chemotherapy. 
 
 
Novel regulatory mechanisms in cardiac and skeletal muscle metabolism 
Over the past decade, AMPK has emerged as a key player in the regulation of myocardial 
metabolism in response to ischemia, pressure overload and heart failure. Lawrence 
Young (Yale) discussed AMPK regulation of mitochondrial function after ischemia/ 
reperfusion. He also spoke about the therapeutic potential of D-dopachrome 
tautomerase (DDT), a novel secreted protein from cardiomyocytes with important 
autocrine/paracrine actions, for preventing cardiac injury during ischemia (Qi et al., 
2014). Interestingly, the cardioprotective effect of DDT requires downstream AMPK 
activation via a calcium-dependent, energy-independent mechanism implicating 
CaMKKas the primary upstream kinase. Beside this protective action during 
myocardial ischemia, AMPK activation also limits the development of cardiac myocyte 
hypertrophy and increases cardiomyocyte response to insulin. Luc Bertrand (Université 
catholique de Louvain) described new molecular mechanisms and AMPK downstream 
targets involved in its insulin-sensitizing and anti-hypertrophic actions. Sandrine 
Horman (Université catholique de Louvain) presented evidence that AMPK1 plays a 
critical role in in cardiac fibroblasts/ myofibroblast biology, providing new perspectives 
and potential therapeutic approaches that could counter the adverse left ventricular 
remodeling of infarcted hearts (Noppe et al., 2014). 
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Erik Richter and Jorgen Wojtaszewski (both University of Copenhagen) reminded us of 
the important role of AMPK in skeletal muscle metabolism in response to exercise, both 
in terms of glucose uptake and fatty acid oxidation. Erik Richter explored the relative 
role of AMPK and Ca2+in increasing glucose uptake during muscle contraction and 
demonstrated that both metabolic activation of AMPK and Rac1-dependent 
rearrangement of the actin cytoskeleton, but not Ca2+released from the sarcoplasmic 
reticulum, fully account for contraction-induced muscle glucose transport (Jensen et al., 
2014). Jorgen Wojtaszewski highlighted the differences in the fiber type-specific 
expression and regulation of AMPK during exercise in humans (Kristensen et al., 2015). 
He also discussed the importance of AMPK in fatty acid oxidation during exercise (Fentz 
et al., 2015) and provided evidence to support that AMPKactivation is sufficient to 
increase skeletal muscle insulin sensitivity (Kjobsted et al., 2014). 
 
 
Toward new AMPK activators and therapeutic applications 
Numerous investigators and major pharmaceutical companies have identified AMPK as 
a potential target for pharmacologic development in the fields of diabetes, obesity, 
ischemic heart disease, atherosclerosis, and cancer. In parallel with rapid scientific 
discovery, pharmaceutical companies are developing specific, direct-acting AMPK 
agonists that are critically important for pre-clinical translational studies and early stage 
clinical investigation to progress.Mark Rider (de Duve Institute andUniversité 
catholique de Louvain) focused on the effect of the small molecule AMPK activator 991 
on glucose uptake in skeletal muscle(Beiroa et al., 2014). Incubation of rat epitrochlearis 
muscle dose-dependently increases activity of AMPK complexes containing various 
combination of 1-, 2-, 1- or2-subunits. Importantly, this work revealed that 
compound 991 increases glucose uptake in an AMPK-dependent manner. Jérôme 
Tamburini (Inserm, CNRS, Université Paris Descartes) employed a novel AMPK activator 
GSK621 as a therapeutic agent in acute myeloid leukemia (AML). Rather unexpectedly, 
mTORC1 activity correlated with the degree of GSK621-induced cytotoxicity and defines 
a mechanism of synthetic lethality with AMPK activation(Sujobert et al., 2015). It is 
noteworthy that GSK621 has no effect on normal CD34+ hematopoietic progenitor cells, 
adding support for the development of AMPK activators as promising therapeutic 
molecules in AML.Benoit Viollet (Inserm, CNRS and Université Paris Descartes) defined 
the AMPK-dependent and -independent metabolic actions of indirect and direct AMPK 
activators on hepatic metabolism. Using mice lacking expressionof both AMPK1/2 
catalytic subunits in the liver, it wasestablished that AMPK is dispensable for metformin- 
and AICAR-mediated suppression of glucose production in primary hepatocytes and the 
AICAR-induced decrease in glucose levels seenin vivo(Foretz et al., 2010; Hasenour et al., 
2014). In contrast, these drugs, as well as the small molecule AMPK activators A-769662 
and compound-13 are ineffective in inhibiting lipogenesis in the absence of hepatic 
AMPK (Hunter et al., 2014). Angela Woods (MRC Clinical Sciences Centre) presented 
data using a new genetic model for determining the effect of activation of AMPK in vivo. 
In the liver, expression of a mutant 1 subunit lead to increased basal activity of AMPK, 
but surprisingly did not lower lipid levels on mice fed either a normal or high fat diet. 
Greg Steinberg (McMaster University) looked at the functional effects of metformin in 
combination with salicylate on hepatic metabolism. The two drugs synergistically 
activate AMPK and greatly enhanced the inhibition of lipogenesis in murine and human 
hepatocytes(Ford et al., 2015).In addition, low dose metformin and salicylate co-
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treatment synergistically reduced fatty liver and enhanced insulin sensitivity in mice fed 
a high fat diet. These results reinforce the view that combinatorial treatments would be 
of value to enhance AMPK activation and help to reduce the concentrationof individual 
drugs administrated to patients. 
 
 
Integrating LKB1 and AMPK-related kinases in the regulation of metabolism 
LKB1 is a master kinase that phosphorylates and activates AMPK and also a family of 12 
closely related protein kinases, including SIK (salt-induced kinase), MARK (microtubule-
affinity-regulating kinase) and BRSK (brain-specific kinase). A currently debated issue is 
the precise role of the AMPK and AMPK-related protein kinases in mediating the 
downstream effects of LKB1on metabolism. In this context, Kei Sakamoto (Nestlé 
Institute of Health Sciences SA)talked about the critical contribution of SIK family 
members in the LKB1-mediated suppression of hepatic gluconeogenesis gene 
transcription by regulating downstream transcription factors/co-activators(Patel et al., 
2014). These findings support a model where the LKB1–SIKsbut not LKB1-AMPK 
pathway functions as a key gluconeogenic gatekeeper in the liver.Robert Screaton 
(Children’s Hospital of Eastern Ontario Research Institute) looked at the function of SIK2 
in pancreatic -cells and the control of glucose homeostasis. By the use of mice deficient 
in SIK2 in adult -cells, it was found that SIK2 is required for glucose-induced insulin 
secretion and is essential for adaptive β-cell functional compensation in models of 
hyperglycaemia(Sakamaki et al., 2014). SIK2 phosphorylates the cyclin-dependent 
kinase 5 activator 1 CDK5R1/ p35to trigger its ubiquitylation by the E3 ligase PJA2, 
resulting in activation of calcium signaling and insulin secretion. Of note, SIK2 has a 
specific role in regulating insulin secretion as silencing SIK1 or SIK3 had no effect in this 
regard. Olga Göransson (Lund University) also highlighted the importance of SIK2 in the 
regulation of metabolic processes. Shefocusedon the molecular targets and functions of 
SIK2 in adipocytes. Based on recent work, she showed data from primary 
adipocytesdemonstrating the roleof SIK2 in the regulation of GLUT4 levels and glucose 
uptake, potentially through its action on CREB regulated transcriptional coactivators 
(CRTCs) and histone deacetylase (HDAC) 4(Henriksson et al., 2015).Kristopher Clark 
(University of Dundee)discussed the therapeutic potential of targeting the SIKs for the 
treatment of chronic inflammatory diseases. Previous work has revealed that inhibition 
of the SIKs with the pan-SIK inhibitor HG-9-91-01elevates the production of anti-
inflammatory cytokines, while suppressing the production of pro-inflammatory 
cytokines in macrophages. He described the SIKs as major targets of the anti-cancer 
drugs bosutinib and dasatinib that mediate the effects of these drugs on the innate 
immune system (Ozanne et al., 2015). He proposed to repurposethese therapeutics for 
the treatment of chronic inflammatory diseases. 
 
Guy Rutter (Imperial College London) investigated the respective roles for LKB1 and 
AMPK in the control of -cell identity. In this context, although LKB1 and AMPK 
signaling only partly overlap to maintain -cell identity, theyact by suppressing the 
expression of different subsets of hepatic and neuronal genes (Kone et al., 2014). Biplab 
Dasgupta (Cincinnati Children’s Hospital Medical Center)presented an example forthe 
differential role of LKB1 and AMPK in the regulation of cell metabolism. He found that 
LKB1 is a key player in the metabolic reprogramming (from a glycolytic to oxidative 
metabolism)during differentiation of Schwann cells,whereas AMPK is largely 
dispensable. Schwann cells deficient in LKB1 failed to produce the mitochondrial Krebs 
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cycle substrate citrate, a precursor to cellular lipids, resulting in impaired 
developmental myelination and axonal integrity (Pooya et al., 2014).In order to identify 
additional novel targets for AMPK and its related family members, Reuben Shaw (The 
Salk Institute for Biological Studies) presented a strategy employing in vivo quantitative 
proteomic analysisthrough metabolic labeling of proteins with a heavy stable isotope of 
nitrogen. On-going work concerns the identification and characterization of phospho-
proteinsin metformin-treated wild type versus mice lacking LKB1.  
 
 
The Herbert Young Investigator Awardand poster prizes 
John Kyriakis (Associate Editor at the Journal of Biological Chemistry) presented the 
Herbert Tabor Young Investigator 
Award(http://www.jbc.org/site/home/tabor_award/2014/izreig.xhtml) to Dr. Said 
Izreig (McGill University) for his work on metabolic regulation in lymphoma. 
 
The organizers David Carling and Benoit Viollet awardedClaire Speirs (University of 
Glasgow) and Pablo Hollstein (The Salk Institute for Biological Studies) prizes for the 
best poster presentations illustrating the crosstalk between AMPK and JAK-STAT 
pathway and the control of cell motility through LKB1-MARK signaling, respectively. 
 
 
Concluding remarks 
This conference showcased the advances that have been made in the understanding of 
the mechanisms of AMPK regulation andour current knowledge of new downstream 
targets and signaling pathways controlled by AMPK. Given the significance of these 
findings and the new questions that they raise, we anticipate that the next meetings on 
AMPKand AMPK-related protein kinases will be equally exciting. Remaining challenges 
in the field include the translation of basic research into therapeutic approaches and the 
development of therapeutics, such as isoform-specific small molecule AMPK activators. 
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Figure 1:Attendees of the FASEB Science Research Conference,AMPK: biological action 
and therapeutic perspectives in Lucca, Italy (September 28 - October 3, 2014). 
 
